Leverencefalopati

Dette dokumentet er basert på det profesjonelle dokumentet Leverencefalopati. Referanselisten for dette dokumentet vises nedenfor.

1. Ferenci P. Hepatic encephalopathy in adults: Clinical manifestations and diagnosis. UpToDate, last updated Feb 19, 2019. UpToDate 
2. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007 Feb. 25 Suppl 1:3-9.
3. Wolf DC. Hepatic encephalopathy. Medscape, last updated Apr 04, 2019. emedicine.medscape.com 
4. Brusilow SW, Koehler RC, Traystman RJ, and Cooper AJ. Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy. Neurotherapeutics, 2010; 7:452–470.
5. Olde Damink S, Deutz N, Dejong C, Soeters P, Jalan R. Interorgan ammonia metabolism in liver failure. Neurochem Int 2002; 41: 177-88. PubMed 
6. Olde Damink S, Deutz N, Redhead D, Hayes P, Soeters P, Jalan R. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36: 1163-71. PubMed 
7. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 2005; 365: 431-3. PubMed 
8. Cordoba J, Alonso J, Rovira A, et al. The development of low-grade cerebral oedema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. J Hepatol 2001; 35: 598-604. PubMed 
9. Balata S, Olde Damink S, Ferguson K, et al. Changes in neuropsychology, magnetic resonance spectroscopy and magnetization transfer following induced hyperammonemia. Hepatology 2003; 37: 931-39. PubMed 
10. Ferenci P. Hepatic encephalopathy in adults: Treatment. UpToDate, last updated Oct 21, 2019. UpToDate 
11. Cordoba J, Alonso J, Rovira A, et al. The development of low-grade cerebral oedema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. J Hepatol 2001; 35: 598-604. PubMed 
12. Als-Nielsen B, Gluud L, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046-50. British Medical Journal 
13. Liu Q, Duan ZP, Ha dK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-49. PubMed 
14. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy. J Hepatol 2004; 41: 38-43. PubMed 
15. Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD003044. DOI: 10.1002/14651858.CD003044.pub4. DOI 
16. Sharma BC, Singh J, Srivastava S et al. A Randomized Controlled Trial Comparing Lactulose Plus Albumin versus Lactulose alone for Treatment of Hepatic Encephalopathy. J Gastroenterol Hepatol 2016. Epub ahead of print. pmid: 27885712 PubMed 
17. Rahimi RS, Singal AG, Cuthbert JA, et al. Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy: The HELP Randomized Clinical Trial. JAMA Intern Med. 2014 Sep 22
18. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010 Mar 25;362(12):1071-81 PubMed 
19. Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study, Aliment Pharmacol Ther 2011 Oct;34(8):853-61.
20. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013 Jul 23. doi: 10.1038/ajg.2013.219. DOI